Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, Suven Life Sciences has informed that the Board of Directors of the company, at its meeting held today i.e. May 13, 2025, has considered and approved the following along with other business matters. Approved the Audited Standalone and Consolidated Financial Results Took on record and approved the attached Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and financial year ended March 31, 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Reports of the Statutory Auditors.
The above information is a part of company’s filings submitted to BSE.
